What is the consensus rating for CCM stock?
The consensus rating for CONCORD MEDICAL - SPON ADR (CCM) is 42.5 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
CONCORD MEDICAL - SPON ADR (CCM) Forecast, Price Target & Analyst Ratings
NYSE:CCM • US2062772049
Current stock price
3.93 USD
+0.02 (+0.51%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CONCORD MEDICAL - SPON ADR (CCM).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $3.93 to mean target of N/A, Based on 8 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
42.50%
CCM was analyzed by 8 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about CCM.
In the previous month the buy percentage consensus was at a similar level.
CCM was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 472.085M -2.78% | 537.402M 13.84% | 383.956M -28.55% | |
| EBITDA YoY % growth | -392.234M -10.74% | -334.531M 14.71% | -401.403M -19.99% | |
| EBIT YoY % growth | -525.048M -14.56% | -462.985M 11.82% | -532.16M -14.94% | |
| Operating Margin | -111.22% | -86.15% | -138.60% | |
| EPS YoY % growth | N/A | N/A | N/A |
All data in CNY
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in CNY
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A